A new map of Europe’s substance-use challenges

The European drug index: Measuring and comparing national substance use across the European Union to aid policy and planning.

The International journal on drug policy • • Moderately Relevant
🤖

AI Summary

This paper introduces the European Drug Index, a framework designed to compare substance use and related responses across 27 EU member states. It combines 151 indicators covering substance use prevalence, treatment coverage, syringe distribution, and overdoses, with results organized by age, gender, and substance class—including cannabis, alcohol, tobacco, and opioids. The index is intended to give policymakers a broader view than any single indicator can provide.

The abstract reports that average EU performance was generally poor or moderate, with stronger performance often seen for legal substances than illegal ones. Regional and demographic differences also emerged: Eastern Europe generally performed better than Western Europe, and results for younger populations did not always match those for older populations. For cannabis users and advocates, the main significance is that the tool could support more nuanced, evidence-based planning—but it does not itself measure the effects of cannabis or establish which policies cause better outcomes.

💡 Key Findings

1
Researchers combined 151 indicators across 27 EU member states to create a comparative substance-use index covering prevalence, treatment, syringe distribution, and overdoses.
High
80%
2
Average performance across the EU was generally poor or moderate, while more countries performed strongly on indicators for legal substances than for illegal substances such as cannabis.
Good
75%
3
The index revealed regional and demographic differences: Eastern Europe generally performed better than Western Europe, and strong performance among younger populations did not necessarily predict strong performance among older populations.
Good
75%
4
The authors conclude that the index could become a valuable tool for evidence-based policy and intervention planning, although it requires further development and analysis.
High
80%

📄 Original Abstract

Despite individual European-wide indicators, there is a dearth of tools that holistically assess substance use and related problems. To address this critical research gap, this paper presents a method used to construct aggregated indices that measure and compare the prevalence of substance use, treatment coverage, syringe distribution, and overdoses per capita across the EU as a whole and by age, gender, and substance class. An indicator-based approach was used to create aggregated indices from 151 indicators for 27 EU member states. Indicators were classified, and aggregate indices were created, for distinct cohorts (e.g., general population, male, female, younger, and older) and substances (e.g., alcohol, cannabis, tobacco, opioids). The average EU performance for most indicators was considered either poor or moderate. General patterns emerged where Eastern Europe performed better than Western Europe, and more nations performed strongly on indices related to legal rather than illegal substances. Nations that were among the highest performers in the Male Index were among the highest performers in the Female Index. Nations that performed well in the Younger Index did not necessarily perform well in the Older Index, except Portugal, which achieved high rankings in both. The results highlight the need for a more thorough analysis of substance use indicators and a nuanced and evidence-based approach to substance use policymaking. As an initial exploration, the index presents a potentially uniquely valuable tool that can be further developed to directly inform policy and intervention development.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.